Nestlé to Buy Biopharmaceutical Company Aimmune - CFO
1 min read
fairly difficult
Aimmune developed a peanut allergy treatment that was approved by the FDA in January.
Nestlé has reached a deal to buy biopharmaceutical company Aimmune Therapeutics for $34.50 per share in cash, a 174% premium to Aimmune's closing price on August 28.

Nestlé already owns a 25.6% stake in the company.

Nestlé Health chief executive officer Greg Behar said Nestlé's prior investment means it is making a cash payment of just under $2 billion.

The companies said the deal represents an enterprise value of $2.6 billion.

Aimmune is the maker of Palforzia, the first peanut allergy treatment approved for use in the U.S. Peanut allergies affect an estimated 1.6 million young people in the U.S.…
William Sprouse
Read full article